CA2567352A1 - 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes - Google Patents

5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes Download PDF

Info

Publication number
CA2567352A1
CA2567352A1 CA002567352A CA2567352A CA2567352A1 CA 2567352 A1 CA2567352 A1 CA 2567352A1 CA 002567352 A CA002567352 A CA 002567352A CA 2567352 A CA2567352 A CA 2567352A CA 2567352 A1 CA2567352 A1 CA 2567352A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkoxy
methoxy
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002567352A
Other languages
English (en)
French (fr)
Inventor
Louis-David Cantin
Xin Ma
Christiana Akuche
Sidney X. Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2567352A1 publication Critical patent/CA2567352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002567352A 2004-05-20 2005-05-20 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes Abandoned CA2567352A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57306604P 2004-05-20 2004-05-20
US60/573,066 2004-05-20
PCT/US2005/017889 WO2005112923A2 (en) 2004-05-20 2005-05-20 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CA2567352A1 true CA2567352A1 (en) 2005-12-01

Family

ID=35428833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002567352A Abandoned CA2567352A1 (en) 2004-05-20 2005-05-20 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes

Country Status (5)

Country Link
US (1) US20080009531A1 (https=)
EP (1) EP1750698A4 (https=)
JP (1) JP2007538102A (https=)
CA (1) CA2567352A1 (https=)
WO (1) WO2005112923A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080032155A (ko) * 2005-07-06 2008-04-14 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
KR20100008382A (ko) 2007-05-18 2010-01-25 시오노기세이야쿠가부시키가이샤 11β-하이드록시스테로이드 탈수소효소 유형 1 저해 활성을 갖는 질소-함유 헤테로환형 유도체
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
US11312722B2 (en) * 2019-05-08 2022-04-26 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000212141A (ja) * 1999-01-13 2000-08-02 Warner Lambert Co ジアリ―ルアミン
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
WO2002088090A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
AR042067A1 (es) * 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes

Also Published As

Publication number Publication date
WO2005112923A2 (en) 2005-12-01
US20080009531A1 (en) 2008-01-10
EP1750698A4 (en) 2010-06-02
WO2005112923A3 (en) 2006-09-14
EP1750698A2 (en) 2007-02-14
JP2007538102A (ja) 2007-12-27

Similar Documents

Publication Publication Date Title
JP6073464B2 (ja) 血小板凝集を治療するためのプロテアーゼ活性化受容体4(par4)阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体
KR101589332B1 (ko) 2h-크로멘 화합물 및 그의 유도체
US20090209451A1 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
JP7476216B2 (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
CA3059107A1 (en) Isoindolin-1-one derivatives and pharmaceutical compositions thereof useful as aski inhibitor
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
KR20110031367A (ko) 화합물 251
CN110156770A (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
KR20030019555A (ko) 프로판-1,3-디온 유도체
CN113195490A (zh) 三唑并吡啶-3-酮或其盐和包含其的药物组合物
AU2020221370A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
CA2743489A1 (en) Substituted bicyclic amines for the treatment of diabetes
CA2620425A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
CA2567352A1 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
SG178043A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
EP3924337A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
GB2640329A (en) Hedgehog acyltransferase inhibitors
CN120359220A (zh) 苯并咪唑衍生物
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
FZDE Dead